Table 2.
Summary of Drug Resistance Characteristics of Participants at Virological Failure With Tenofovir + Cytosine Analog + NNRTI by Geographical Region
| Region | M184 I/V | TDF Resistance, n (%) | At Least One Major NNRTI Mutation, n (%) | Number of NNRTI Mutations, Mean (SD) | Failure Log10 Viral Load | Failure CD4 Count | |
|---|---|---|---|---|---|---|---|
| N With Data | Median (IQR) | ||||||
| Overall | No | 137 (21.8%) | 380 (60.5%) | 1.2 (1.3) | 4.3 (3.4 to 5.0) | 237 | 263.0 (121.0 to 382.0) |
| Yes | 539 (66.0%) | 792 (96.9%) | 2.9 (1.3) | 4.7 (4.1 to 5.3) | 211 | 104.0 (29.0 to 236.0) | |
| Sub-saharan Africa | No | 80 (31.1%) | 175 (68.1%) | 1.5 (1.4) | 4.7 (3.9 to 5.2) | 29 | 262.0 (180.0 to 360.0) |
| Yes | 400 (73.7%) | 531 (97.8%) | 2.9 (1.3) | 4.8 (4.1 to 5.3) | 52 | 137.0 (20.0 to 219.0) | |
| Asia | No | 30 (22.1%) | 91 (66.9%) | 1.3 (1.4) | 4.8 (4.1 to 5.3) | 119 | 188.0 (71.0 to 355.0) |
| Yes | 82 (58.2%) | 130 (92.2%) | 2.9 (1.5) | 4.9 (4.2 to 5.3) | 118 | 87.5 (29.0 to 229.0) | |
| Europe | No | 20 (13.7%) | 65 (44.5%) | 0.7 (1.0) | 3.4 (2.7 to 4.6) | 32 | 323.0 (238.0 to 387.0) |
| Yes | 38 (43.2%) | 86 (97.7%) | 2.6 (1.4) | 4.2 (3.8 to 4.8) | 12 | 242.5 (122.0 to 345.0) | |
| North America | No | 7 (7.9%) | 49 (55.1%) | 0.8 (0.9) | 3.4 (2.4 to 4.3) | 57 | 312.0 (198.0 to 476.0) |
| Yes | 19 (42.2%) | 45 (100.0%) | 2.8 (1.4) | 4.2 (3.7 to 4.7) | 29 | 173.0 (42.0 to 329.0) |
Abbreviations: IQR, interquartile range; NNRTI, nonnucleoside reverse-transcriptase inhibitor; SD, standard deviation; TDF, tenofovir disoproxil fumarate.